Beleave Inc. Share Price

BLEVF

CA0775611084

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:51:53 04/04/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2020	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
2020	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI

Latest news about Beleave Inc.

Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	17/20/17	CI
Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	05/20/05	CI
Beleave Inc. Announces Management Changes	13/20/13	CI
Beleave Inc. announced that it expects to receive CAD 0.5 million in funding	03/20/03	CI
Beleave Inc. Enters LoI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	03/20/03	CI
Beleave Inc. Approves for Sales in the Province of Alberta	03/20/03	CI
Beleave Expands Cannabis 2.0 Product Roll Out to British Columbia with Flyte Classic Vaporizer	26/20/26	CI
Beleave Inc. announced that it has received CAD 0.27 million in funding	26/20/26	CI
Beleave Inc. Announces New Product Line; Receives the Largest Purchase Order from A Province in the Company's History	19/19/19	CI
Beleave Inc. Announces Management Changes	19/19/19	CI
Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada	31/19/31	CI
Beleave Inc. Announces Management Appointments	28/19/28	CI
Beleave Inc. (CNSX:BE) cancelled its acquisition of TerraFarma, Inc.	19/19/19	CI
Beleave Inc. (CNSX:BE) entered into a non-binding letter of intent to acquire TerraFarma, Inc.	07/19/07	CI
Beleave Inc. Announces Restated Interim Consolidated Financial Statements for the Nine Months Ended December 31, 2018	29/19/29	CI

More news

Highs and lows

Current year

0.00

1 year

0.00

3 years

0.00

0.01

5 years

0.00

0.08

10 years

0.00

0.40

More quotes

Managers and Directors - Beleave Inc.

Managers	Title	Age	Since
Bill Panagiotakopoulos FOU	Founder	-	26/00/26
Roger Ferreira CTO	Chief Tech/Sci/R&D Officer	-	15/15/15
Kevin Keagan BRD	Director/Board Member	-	24/18/24

Members of the board	Title	Age	Since
Roger Ferreira CTO	Chief Tech/Sci/R&D Officer	-	15/15/15
Bill Panagiotakopoulos FOU	Founder	-	26/00/26
Kevin Keagan BRD	Director/Board Member	-	24/18/24

More insiders

Beleave Inc. is a Canada-based cannabis company. Through its wholly owned subsidiary, Beleave Kannabis Corp, the Company is a license holder and producer of cannabis, which includes cultivation, processing, medical sales and research. Its segment includes Cannabis Products and Patient Network. Its Cannabis Products segment is a licensed producer of marihuana for medical purposes. Its Patient Network segment is a patient network of medical cannabis services. It cultivates cannabis flower, oil and extracts for medical and recreational markets. Its product line includes cannabis-infused products, oils and vape pens. The Company operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
BELEAVE INC.	0.00%	553
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine

Sales 2018	-	Sales 2019	2.37 197.95	Capitalization	30.37M 2.53B
Net income 2018	-12M -1B	Net income 2019	-33M -2.75B	EV / Sales 2018	-
Net cash position 2018	5.2M 434M	Net Debt 2019	10.32M 860M	EV / Sales 2019	1,71,37,012 x
P/E ratio 2018	-4.72 x	P/E ratio 2019	-0.76 x	Employees	-
Yield 2018 *	-	Yield 2019	-	Free-Float	98.39%

Beleave Inc. Share Price

Equities

BLEVF

CA0775611084

Pharmaceuticals

Financials

Chart Beleave Inc.